| Literature DB >> 22687456 |
Alan P Skarbnik1, Mitchell R Smith.
Abstract
Mantle cell lymphoma (MCL), though characterized by the chromosomal translocation t(11; 14) (q13; q32), is a heterogeneous disease. Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy. There is no single standard initial therapy for this disease. Although standard lymphoma therapies yield high response rates, relapse is inevitable. Unmet needs in MCL include better induction therapy, consolidation treatments to prolong first remission and better therapeutic options for relapsed disease. In this review, we evaluate the role of radioimmunotherapy (RIT) in MCL, a novel strategy combining monoclonal antibodies with radioisotopes to deliver radiation directly to tumour tissue, both in the frontline and relapsed setting.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22687456 PMCID： PMC3748580 DOI： 10.1016/j.beha.2012.04.004
Source DB: PubMed Journal: Best Pract Res Clin Haematol ISSN： 1521-6926 Impact factor: 3.020